These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 28238843)

  • 1. Alterations of CXCL12 in Serum of Patients with Vitiligo.
    Speeckaert R; Ongenae K; van Geel N
    J Invest Dermatol; 2017 Jul; 137(7):1586-1588. PubMed ID: 28238843
    [No Abstract]   [Full Text] [Related]  

  • 2. CXCL12 as a Predictor of Vitiligo Activity and Disease Progression.
    Alexeev V
    J Invest Dermatol; 2017 Jul; 137(7):1588-1590. PubMed ID: 28365260
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarkers of disease activity in vitiligo: A systematic review.
    Speeckaert R; Speeckaert M; De Schepper S; van Geel N
    Autoimmun Rev; 2017 Sep; 16(9):937-945. PubMed ID: 28698094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Misbalanced CXCL12 and CCL5 Chemotactic Signals in Vitiligo Onset and Progression.
    Rezk AF; Kemp DM; El-Domyati M; El-Din WH; Lee JB; Uitto J; Igoucheva O; Alexeev V
    J Invest Dermatol; 2017 May; 137(5):1126-1134. PubMed ID: 28132854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profile of genes associated with the dopamine pathway in vitiligo skin biopsies and blood sera.
    Reimann E; Kingo K; Karelson M; Reemann P; Loite U; Keermann M; Abram K; Vasar E; Silm H; Kõks S
    Dermatology; 2012; 224(2):168-76. PubMed ID: 22572099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA.
    Macoska JA; Begley LA; Dunn RL; Siddiqui J; Wei JT; Sarma AV
    Prostate; 2008 Mar; 68(4):442-52. PubMed ID: 18196514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo.
    Vaccaro M; Cannavò SP; Imbesi S; Cristani M; Barbuzza O; Tigano V; Gangemi S
    Int J Dermatol; 2015 Jun; 54(6):672-4. PubMed ID: 25427848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I interferon signature in the initiation of the immune response in vitiligo.
    Bertolotti A; Boniface K; Vergier B; Mossalayi D; Taieb A; Ezzedine K; Seneschal J
    Pigment Cell Melanoma Res; 2014 May; 27(3):398-407. PubMed ID: 24438589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a relationship between homocysteine and vitiligo? A pilot study.
    Shaker OG; El-Tahlawi SM
    Br J Dermatol; 2008 Sep; 159(3):720-4. PubMed ID: 18616781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vogt-Koyanagi-Harada syndrome following injury-induced progressive vitiligo.
    Gupta V; Gupta A; Bambery P; Radotra BD; Pandav SS
    Indian J Ophthalmol; 2001 Mar; 49(1):53-5. PubMed ID: 15887718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo.
    Bhardwaj S; Rani S; Srivastava N; Kumar R; Parsad D
    Cytokine; 2017 Mar; 91():153-161. PubMed ID: 28082234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced immunohistochemical expression of adhesion molecules in vitiligo skin biopsies.
    Reichert Faria A; Jung JE; Silva de Castro CC; de Noronha L
    Pathol Res Pract; 2017 Mar; 213(3):199-204. PubMed ID: 28214208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi.
    van Geel NA; Mollet IG; De Schepper S; Tjin EP; Vermaelen K; Clark RA; Kupper TS; Luiten RM; Lambert J
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):375-84. PubMed ID: 20370855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Significance of Serum Soluble CD Molecules to Assess Disease Activity in Vitiligo.
    Speeckaert R; Lambert J; van Geel N
    JAMA Dermatol; 2016 Nov; 152(11):1194-1200. PubMed ID: 27556155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical study before and after narrow band (311 nm) UVB treatment in vitiligo.
    De Francesco V; Stinco G; Laspina S; Parlangeli ME; Mariuzzi L; Patrone P
    Eur J Dermatol; 2008; 18(3):292-6. PubMed ID: 18474458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo.
    Birol A; Kisa U; Kurtipek GS; Kara F; Kocak M; Erkek E; Caglayan O
    Int J Dermatol; 2006 Aug; 45(8):992-3. PubMed ID: 16911396
    [No Abstract]   [Full Text] [Related]  

  • 17. Oxidation products are increased in patients affected by non-segmental generalized vitiligo.
    Vaccaro M; Bagnato G; Cristani M; Borgia F; Spatari G; Tigano V; Saja A; Guarneri F; Cannavò SP; Gangemi S
    Arch Dermatol Res; 2017 Aug; 309(6):485-490. PubMed ID: 28551758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and morphological study of the skin in patients with vitiligo during treatment with psoralen].
    Arutiunov VIa; Arkhangel'skaia NV; Uzhvieva NV
    Vestn Dermatol Venerol; 1972 Feb; 46(2):8-12. PubMed ID: 5036805
    [No Abstract]   [Full Text] [Related]  

  • 19. IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo.
    Vaccaro M; Cicero F; Mannucci C; Calapai G; Spatari G; Barbuzza O; Cannavò SP; Gangemi S
    Arch Dermatol Res; 2016 Sep; 308(7):527-30. PubMed ID: 27388717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of elevated CXCR4 and CXCL12 in neonatal sepsis.
    Tunc T; Cekmez F; Cetinkaya M; Kalayci T; Fidanci K; Saldir M; Babacan O; Sari E; Erdem G; Cayci T; Kul M; Kavuncuoglu S
    J Matern Fetal Neonatal Med; 2015 Feb; 28(3):356-61. PubMed ID: 24749796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.